Skip to main content
SpringerLink
Log in

5-HT3 Receptor Antagonists for the Prevention of Chemotherapy-Induced Nausea and Vomiting

A Comparison of Their Pharmacology and Clinical Efficacy

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Summary

In the mid-1980s it was discovered that serotonin (5-hydroxytryptamine; 5-HT) was at least partially responsible for producing chemotherapy-induced nausea and vomiting. It was therefore realised that serotonin receptor blockade with serotonin 5-HT3 receptor antagonists could inhibit chemotherapy-induced nausea and vomiting.

5-HT3 antagonists have different chemical structures and receptor binding affinity. Granisetron, dolasetron and its major metabolite are pure 5-HT3 antagonists, while ondansetron and tropisetron are weak antagonists at the 5-HT4 receptor. Ondansetron has also been demonstrated to bind at other serotonin receptors and to the opioid µ receptor.

The half-lives of granisetron, tropisetron and the active metabolite of dolasetron are 2 to 3 times longer than that of ondansetron. These observations initially suggested that more frequent ondansetron administration would be required; however, it has now been shown that receptor blockade does not correlate with elimination half-life and all 5-HT3 antagonists can be effectively administered once daily.

Clinical trials have been conducted that directly compare the 5-HT3 antagonists. To compare these studies, it is necessary to assess trial design, including known risk factors for the development of chemotherapy-induced nausea and vomiting, and response criteria. Stratification for risk factors, use of strict efficacy criteria and randomisation to a blinded trial using an appropriate comparative regimen are essential for a well designed antiemetic trial.

Comparative clinical trials using various doses, routes and regimens of administration have been conducted with 5-HT3 antagonists. Despite some trial design shortcomings, most of the studies show equal efficacy between the agents, especially in moderately emetogenic chemotherapy and mild, infrequently occurring adverse effects. The addition of steroids also appears to improve outcome. However, since many doses and regimens of ondansetron were used, further study is needed to determine the optimal regimen.

The efficacy of 5-HT3 antagonists in controlling delayed nausea and vomiting from chemotherapy is less well studied. Further, there is no good scientific rationale for the use of 5-HT3 antagonists in controlling delayed nausea and vomiting since serotonin has not been shown to be released during the delayed phase. In fact, most studies show no benefit or modest benefit of 5-HT3 antagonists over placebo.

Because the 5-HT3 antagonists perform similarly in the clinical setting, pharmacological differences do not seem to translate into therapeutic differences. There is also no appreciable difference in the incidence or severity of adverse effects among the 5-HT3 antagonists. Determination of clinical use may then be driven by cost.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Craig JB, Powell BL. The management of nausea and vomiting in clinical oncology. Am J Med Sci 1987; 293: 34–44

    Article  PubMed  CAS  Google Scholar 

  2. Veyrat-Follet C, Farinotti R, Palmer JL. Physiology of chemotherapy-induced emesis and antiemetic therapy: predictive models for evaluation of new compounds. Drugs 1997 Feb; 53(2): 206–34

    Article  PubMed  CAS  Google Scholar 

  3. Leslie RA. Neuroactive substances in the dorsal vagal complex of the medulla oblongata: nucleus of the tractus solitarius, area postrema, and dorsal motor nucleus of the vagus. Neurochem Int 1985; 7: 191–211

    Article  PubMed  CAS  Google Scholar 

  4. Miner WD, Sanger GJ. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 1986; 88: 497–9

    Article  PubMed  CAS  Google Scholar 

  5. Andrews PLR, Rapeport WG, Sanger GJ. Neuropharmacology of emesis induced by anticancer therapy. Trends Pharmacol Sci 1988; 9: 334–41

    Article  PubMed  CAS  Google Scholar 

  6. Leslie RA, Shah Y, Thejomayen M, et al. The neuropharmacology of emesis: the role of receptors in neuromodulation of nausea and vomiting. Can J Physiol Pharmacol 1990; 68: 279–88

    Article  PubMed  CAS  Google Scholar 

  7. Alfieri AB, Cebeddu LX. Treatment with para-chlorophenylalanine antagonises the emetic response and the serotonin-releasing actions of cisplatin in cancer patients. Br J Cancer 1995; 71: 629–32

    Article  PubMed  CAS  Google Scholar 

  8. Fozard JR. 5-HT3 receptors and cytotoxic drug-induced vomiting. Trends Pharmacol Sci 1987; 8: 44–5

    Article  CAS  Google Scholar 

  9. Gyermek L. 5-HT3 receptors: pharmacologie and therapeutic aspects. J Clin Pharmacol 1995; 35: 845–55

    PubMed  CAS  Google Scholar 

  10. Blower P. A pharmacologie profile of oral granisetron. Semin Oncol 1995 Aug; 22 (4 Suppl. 10): 3–5

    PubMed  CAS  Google Scholar 

  11. Sancillo LF, Pinkus LM, Jackson CB, et al. Emetic activity of zacopride in ferrets and its antagonism by pharmacological agents. Eur J Pharmacol 1990; 181: 303–6

    Article  Google Scholar 

  12. Van Wijngaarden I, Tulp MTM, Soudijn W. The concept of selectivity in 5-HT receptor research. Eur J Pharmacol 1990; 188: 301–312

    Article  PubMed  Google Scholar 

  13. Andrews PLR, Blower PR. The physiology of cytotoxic-induced emesis: new insights. Presented at a Satellite to the Seventh European Conference of Clinical Oncology Meeting; 1993 Nov; Jerusalem, 14–7

  14. Andrews PLR, Bhandari P, Davey PT, et al. Are all 5-HT receptor antagonists the same? Eur J Cancer 1992; 28 Suppl. A: S2–6

    Article  Google Scholar 

  15. Lazarus HM, Bryson JC, Lemon E, et al. Antiemetic efficacy and pharmacokinetic analyses of the serotonin antagonist ondansetron (GR 38032F) during multiple-day chemotherapy with cisplatin prior to autologous bone marrow transplantation. J Natl Cancer Inst 1990; 82: 1776–8

    Article  PubMed  CAS  Google Scholar 

  16. Addelman M, Erlichman C, Fine S, et al. Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting. J Clin Oncol 1990; 8: 337–41

    PubMed  CAS  Google Scholar 

  17. Carmichael J, Cantwell BMJ, Edwards CM, et al. A pharmacokinetic study of granisetron (BRL43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response. Cancer Chemother Pharmacol 1989; 24: 45–9

    Article  PubMed  CAS  Google Scholar 

  18. Cassidy J, Raina V, Lewis C, et al. Pharmacokinetics and anti-emetic efficacy of BRL 43694, a new selective 5-HT3 antagonist. Br J Cancer 1988; 58: 651–3

    Article  PubMed  CAS  Google Scholar 

  19. de Bruijn KM. Tropisetron: a review of the clinical experience. Drugs 1992; 43 Suppl. 3: 11–22

    Article  PubMed  Google Scholar 

  20. Shah AK, Bhargava VO, Hahne WF, et al. Population pharmacokinetics and pharmacodynamics of metabolite after intravenous administration of dolasetron mesylate in patients receiving cisplatin chemotherapy [abstract]. Pharm Res 1995; 12 Suppl. 9: S360

    Google Scholar 

  21. Bonneterre J, Hecquet B, French Northern Oncology Group. Granisetron (IV) compared with ondansetron (IV plus oral) in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a cross-over study. Bull Cancer 1995 Dec; 82: 1038–43

    PubMed  CAS  Google Scholar 

  22. Noble A, Bremer K, Goedhals L, et al. A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. Eur J Cancer 1994; 30(8): 1083–8

    Article  Google Scholar 

  23. Navari R, Gandara D,Hesketh P, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995 May; 13(5): 1242–8

    PubMed  CAS  Google Scholar 

  24. Ruff P, Paska W, Goedhals L, et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. Oncology 1994; 51: 113–8

    Article  PubMed  CAS  Google Scholar 

  25. Stewart A, McQuade B, Cronje JDE, et al. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double dummy, randomised, parallel-group study. Oncology 1995; 52: 202–10

    Article  PubMed  CAS  Google Scholar 

  26. Gebbia V, Cannata G, Testa A, et al. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Cancer 1994 Oct; 74(7): 1945–52

    Article  PubMed  CAS  Google Scholar 

  27. Martoni S, Angelelli B, Guaraldi M, et al. Granisetron (GRA) vs. ondansetron (OND) in the prevention of cisplatinum-induced emesis: an open randomized cross-over study [abstract]. Proc Am Soc Clin Oncol 1993; 13: 431

    Google Scholar 

  28. Leonardi V, Iannitto E, Meli M, et al. Ondansetron vs granisetron in the control of chemotherapy induced acute emesis: a multicentric randomized trial. Oncol Rep 1996; 3: 919–23

    PubMed  CAS  Google Scholar 

  29. Italian Group for Antiemetic Research. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 1995 Oct; 6: 805–10

    Google Scholar 

  30. Marty M, Kleisbauer J-P, Fournel P, et al. Is Navoban® (tropisetron) as effective as Zofran® (ondansetron) in cisplatin-induced emesis? Anti-Cancer Drugs 1995; 6 Suppl. 1: 15–21

    Article  PubMed  CAS  Google Scholar 

  31. Jantunen IT, Kataja VV, Johansson RT. Ondansetron and tropisetron with dexamethasone in the prophylaxis of acute nausea and vomiting induced by non—cisplatin-containing chemotherapy. Acta Oncol 1992; 31(3): 573–5

    Article  PubMed  CAS  Google Scholar 

  32. Campora E, Simoni C, Rosso R. Tropisetron verso ondansetron nella prevenzione e controllo dell’emesi in pazienti sottoposte a chemioterapia con FAC/FEC per carcinoma mammario metastatico o operato. Minerva Med 1994; 85: 25–31

    PubMed  CAS  Google Scholar 

  33. Massidda B, Laconi S, Foddi MR, et al. Prevention of non-cisplatin induced emesis: role of the antagonists of 5-HT3 receptors [abstract]. Ann Oncol 1994; 5 Suppl. 8: 204

    Google Scholar 

  34. Mantovani A, Maccio L, Curreli L, et al. Comparison of the effectiveness of three 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by highly emetogenic chemotherapy (high-dose cisplatin) for the treatment of primary head and neck cancer [abstract]. Proc Soc Am Clin Oncol 1994; 13: 428

    Google Scholar 

  35. Jantunen IT, Muhonen TT, Kataja VV, et al. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy — a randomised study. Eur J Cancer 1993; 29A: 1669–72

    Article  PubMed  CAS  Google Scholar 

  36. Hesketh P, Navari R, Grote T, et al. Double-blind, randomised comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 1996 Aug; 14(8): 2242–9

    PubMed  CAS  Google Scholar 

  37. Audhuy B, Cappelaere P, Martin M, et al. A double-blind, randomised comparison of the antiemetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer 1996 May; 32A(5): 807–13

    PubMed  CAS  Google Scholar 

  38. Lofters WS, Zee B. Dolasetron (DOL) vs ondansetron (OND) with and without dexamethasone (DEX) in the prevention of nausea (N) and vomiting (V) in patients (pts) receiving moderately emetogenic chemotherapy (MEC) [abstract]. Cancer Support Care 1995; 3: 339

    Google Scholar 

  39. Fauser AA, Duclos B, Chemaissani A, et al. Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. Eur J Cancer 1996 Aug; 32A(9): 1523–9

    Article  PubMed  CAS  Google Scholar 

  40. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997; 15: 103–9

    PubMed  CAS  Google Scholar 

  41. Sullivan JR, Leyden MJ, Bell R. Decreased cisplatin-induced nausea and vomiting with chronic alcohol ingestion [letter]. N Engl J Med 1983; 309: 796

    PubMed  CAS  Google Scholar 

  42. Triozzi P, Laszlo J. Optimum management of nausea and vomiting in cancer chemotherapy. Pract Ther Drugs 1987; 24: 136–49

    Google Scholar 

  43. Tonato M, Roila F. Methodology of antiemetic trials. Ann Oncol 1991; 2: 107–14

    Article  PubMed  CAS  Google Scholar 

  44. Kris MG, Gralla RJ, Clark RA, et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985 Oct; 3(10): 1379–84

    PubMed  CAS  Google Scholar 

  45. Fetting JH, Grochow LB, Folstein MF, et al. The course of nausea and vomiting after high-dose cyclophosphamide. Cancer Treat Rep 1982; 66: 1487–93

    PubMed  CAS  Google Scholar 

  46. Morrow GR. Prevalence and correlates of anticipatory nausea and vomiting in chemotherapy patients. J Natl Cancer Inst 1982; 68: 585–8

    PubMed  CAS  Google Scholar 

  47. Roila F, Ballatori E, De Angelis V. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995 Jan; 332: 1–5

    Article  Google Scholar 

  48. Tonato M. Ondansetron plus dexamethasone: an effective combination in high-dose cisplatin therapy. Eur J Cancer 1991; 27 Suppl. 1: S12–4

    PubMed  Google Scholar 

  49. Diehl V, Marty M. Efficacy and safety of antiemetics. Cancer Treat Rev 1994; 20: 379–92

    Article  PubMed  CAS  Google Scholar 

  50. Lee CR, Plosker GL, McTavish D. Tropisetron: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic. Drugs 1993; 46: 925–43

    Article  PubMed  CAS  Google Scholar 

  51. SmithKline Beecham Pharmaceuticals. Granisetron prescribing information. Philadelphia (PA), 1994

  52. Glaxo Wellcome. Ondansetron prescribing information. Research Triangle Park (NC), 1995

  53. Kris MG, Gralla RJ, Tyson LB, et al. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989; 7: 208–14

    Google Scholar 

  54. Wilder-Smith OHG, Borgeat L, Chappuis P, et al. Urinary serotonin metabolite excretion during cisplatin chemotherapy. Cancer 1993; 72: 2239–41

    Article  PubMed  CAS  Google Scholar 

  55. Gandara DR, Harvey WH, Monaghan GG, et al. The delayedemesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo. Semin Oncol 1992 Aug; 19 (4 Suppl. 10): 67–71

    PubMed  CAS  Google Scholar 

  56. De Mulder PHM, Seynaeve C. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 1990; 113: 834–40

    PubMed  Google Scholar 

  57. Jantunen IT, Flander MK, Heikkenin MI, et al. Comparison of ondansetron with customary treatment in the prophylaxis of nausea and emesis induced by non-cisplatin containing chemotherapy. Acta Oncologica 1993; 32(4): 413–5

    Article  PubMed  CAS  Google Scholar 

  58. Jones AL, Hill AS, Soukop M, et al. Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 1991; 338: 483–7

    Article  PubMed  CAS  Google Scholar 

  59. Navari RM, Madajewica S, Anderson N, et al. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol 1995 Sep; 13(9): 2408–16

    PubMed  CAS  Google Scholar 

  60. Rosso R, Campora E, Cetto G, et al. Oral ondansetron (GR 38032F) for the control of acute and delayed cyclophosphamide-induced emesis. Anticancer Res 1991; 11: 937–40

    PubMed  CAS  Google Scholar 

  61. de Wit R, de Boer-Dennert M, Stoter G, et al. Sustainment of efficacy of tropisetron during 6 courses of cisplatin-containing chemotherapy [abstract]. Ann Oncol 1993; 3 Suppl. 5: 185

    Google Scholar 

  62. Sorbe BG, Hauogberg T, Glimelius B, et al. A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail. Cancer 1994 Jan; 73: 445–54

    Article  PubMed  CAS  Google Scholar 

  63. Granisetron Study Group. Incidence of delayed cisplatin-induced emesis following acute antiemetic prophylaxis with granisetron. Presented at Advances in Emetic Control. 15th Union Against Cancer: 1990 Aug 17; Hamburg

  64. Heron JF, Goedhals L, Jordan JP, et al. Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. Ann Oncol 1995; 5: 579–84

    Google Scholar 

  65. Kris MG, Pisters KMW, Hinkley L. Delayed emesis following anticancer chemotherapy. Support Care Cancer 1994; 2: 297–300

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology and Medicine, Johns Hopkins Oncology Center, 600 North Wolfe Street, Baltimore, Maryland, 21287, USA

    R. Elizabeth Gregory &  David S. Ettinger

Authors
  1. R. Elizabeth Gregory
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David S. Ettinger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David S. Ettinger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gregory, R.E., Ettinger, D.S. 5-HT3 Receptor Antagonists for the Prevention of Chemotherapy-Induced Nausea and Vomiting. Drugs 55, 173–189 (1998). https://doi.org/10.2165/00003495-199855020-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199855020-00002

Keywords

Search

Navigation